Characterization and immunogenicity of meningococcal group C conjugate vaccine prepared using hydrazide-activated tetanus toxoid

Vaccine

Volumn 25, Issue 41, 2007, Pages 7261-7270

  Silveira, I A F B ^a   Bastos, R C ^a   Neto, M S ^a   Laranjeira, A P ^a   Assis, E F ^a   Fernandes, S A R ^a   Leal, M L ^a   Silva, W C ^a   Lee, C H ^b   Frasch, C E ^b   Peralta, J M ^c   Jessouroun, E ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Conjugate vaccine; High avidity IgG; Meningococcal group C; Reductive amination; Serum bactericidal activity

Indexed keywords

HYDRAZIDE; IMMUNOGLOBULIN G ANTIBODY; MENINGOCOCCUS TETANUS VACCINE; MENINGOCOCCUS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG CONJUGATION; DRUG DOSE COMPARISON; DRUG PURIFICATION; DRUG QUALITY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; FILTRATION; FREEZE DRYING; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; REACTION TIME; SCALE UP;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY AFFINITY; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG STABILITY; FILTRATION; IMMUNOGLOBULIN G; MENINGOCOCCAL VACCINES; MICE; MICROBIAL VIABILITY; TETANUS TOXOID;

EID: 34648817218     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.07.037     Document Type: Article

References (64)

1. Rosenstein N.E., Perkins B.A., Stephens D.S., Popovic T., and Hughes J.M. Meningococcal disease. N Engl J Med 344 (2001) 1378-1388
2. Richmond P., Borrow R., Miller E., Clark S., Sadler F., Fox A., et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 179 (1999) 1569-1572
3. Richmond P., Kaczmarski E., Borrow R., Findlow J., Clark S., McCann R., et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 181 (2000) 761-764
4. English M., MacLennan J.M., Bowen-Morris J.M., Deeks J., Boardman M., Brown K., et al. A randomized, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infants. Vaccine 19 (2001) 1232-1238
5. Jokhdar H., Borrow R., Sultan A., Adi M., Riley C., Fuller E., et al. Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Clin Diagn Lab Immunol 11 (2003) 83-88
6. Chu C., Schneerson R., Robbins J.B., and Rastogi S.C. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect Immun 40 (1983) 245-256
7. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 13 (2000) 302-317
8. Ramsay M.E., Andrews N., Kaczmarski E.B., and Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 357 (2001) 195-196
9. Fairley C.K., Begg N., Borrow R., et al. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J Infect Dis 174 (1996) 1360-1363
10. Leach A., Twumasi P.A., Kumah S., Banya W.S., Jaffar S., Forrest B.D., et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis 175 (1997) 200-204
11. Ramsay M.E., Andrews N., Trotter C.L., Kaczmarski E.B., and Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 326 (2003) 365-366
12. Report of the Committee on Safety of Medicines Expert Working Group on Meningococcal Group C Conjugate Vaccines; 2002. http://www.mca.gov.uk/ourwork/monitorsafequalmed/safetymessages/mencwgreport.pdf (accessed January 14, 2004).
13. National Disease Surveillance Centre in collaboration with the Irish Meningococcal and Meningitis Reference Laboratory. Enhanced surveillance of bacterial meningitis including meningococcal septicaemia, in Ireland, Annual 2003-provisional figures 2004. http://www.ndsc.ie/Publications/BacterialMeningitisReports/d985.pdf (accessed June 6, 2004).
14. Salleras I., Dominguez A., and Cardenoza N. Impact of mass vaccination with polysaccharide conjugate vaccine against serogroup C meningococcal disease in Spain. Vaccine 21 (2003) 725-728
15. Salleras I., Dominguez A., and Cardenoza N. Dramatic decline of serogroup C meningococcal disease in Catalonia (Spain) after a mass vaccination campaign with meningococcal C conjugated vaccine. Vaccine 21 (2003) 729-733
16. Timen A., and van Steenbergen J.E. Meningitis group C vaccination campaign in the Netherlands. Eur J Public Health 12 (2002) 22
17. Division of Bacteriology, Scientific Institute of Public Health. Report of Neisseria meningitides National Surveillance centre. Belgium; 2002, 2003. http://www.iph.fgov.be/bacterio/iframes/rapports/2002/Men_2002_Fr.pdf (accessed January 6, 2004).
18. Australian Technical Advisory Group on Immunization. Australian immunization handbook. 8th ed. (2003), Australian Government Department of Health and Ageing, Canberra
19. Canadian Paediatric Society. Routine Immunization Schedule; 2004. http://www.cps.ca/english/statements/ID/PIDNotesImmunization.htm (accessed October 16, 2004).
20. Snape M.D., and Pollard A.J. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis 5 (2005) 21-30
21. Ministry of Health, National Foundation of Health. CENEPI: Brazil; 2003.
22. Sifontes S., Infante J.F., Perez P., Caro E., Sierra G., and Campa C. The hyperferremic mouse model for the evaluation of the effectiveness of VA-MENGOC-BC against Neisseria meningitidis B clinical isolates. Arch Med Res 28 (1997) 41-45
23. Jennings H.J., and Lugowski C. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J Immunol 127 (1981) 1011-1018
24. Costantino P., Viti S., Podda A., Velmonte M.A., Nencioni L., and Rappuoli R. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 10 (1992) 691-698
25. Pawlowski A., Källenius G., and Svenson S.B. Preparation of pneumococcal capsular polysaccharide-protein conjugate vaccines utilizing new fragmentation and conjugation technologies. Vaccine 18 (2000) 1873-1885
26. Lees A., Sen G., and LopezAcosta A. Versatile and efficient synthesis of protein-polysaccharide conjugate vaccines using aminooxy reagents and oxime chemistry. Vaccine 24 (2006) 716-729
27. Lee Che-HR, Frasch CE. Polysaccharide-protein conjugate vaccines. Patent pending, US 60/493, 389; WO 2005/014,037 A2; 2005.
28. Jessouroun E, da Silveira IAFB, Bastos RC, Frasch CE, Lee Che-HR. Process for preparing polysaccharide-protein conjugate vaccines. International Publication WO 2005/037320; 2005.
29. Gotschlich E.C., Liu T.Y., and Artenstein M.S. Human immunity to the meningococcus. III. Preparation and immunochemical properties of the group A, group B and group C meningococcal polysaccharides. J Exp Med 129 (1969) 1349-1365
30. World Health Organization. Requirements for meningococcal polysaccharide vaccine. Technical Report Series, No. 658; 1981.
31. Svennerholm L. Quantitative estimation of sialic acids. Biochim Biophys Acta 24 (1957) 604-611
32. Jones C., Crane D.T., Lemercinier B., Bolgiano B., and Yost S.E. Physicochemical studies of the structure and stability of polysaccharide-protein conjugate vaccines. Dev Biol Stand Basel Karger 87 (1996) 143-151
33. World Health Organization. Recommendations for the production and control of meningococcal group C conjugate vaccines. WHO Technical Report, Series No. 924; 2004.
34. Jódar L., Griffiths E., and Feavers I.M. Scientific challenges for the quality control and production of group C meningococcal conjugate vaccines. Vaccine 22 (2004) 1047-1053
35. World Health Organization. Requirements for diphtheria, tetanus, pertussis and combined vaccines. WHO Technical Report Series No. 800; 1990.
36. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248
37. Quensenberry M.S., and Lee Y.C. A rapid formaldehyde assay using Purpald Reagent: application under periodation conditions. Anal Biochem 234 (1996) 50-55
38. Lei Q.P., Shannon A.G., Heller R.K., and Lamb D.H. Quantification of free polysaccharide in meningococcal polysaccharide-diphtheria toxoid conjugate vaccines. Dev Biol Basel Karger 103 (2000) 259-264
39. Wieland G. Water determination by Karl Fischer Titration. Theory and applications (1987), Git Verlag GMBH, Germany
40. Park C.-Y., Jung S.-H., Bak J.-P., Lee S.-S., and Rhee D.-K. Comparison of the rabbit pyrogen test and Limulus amoebocyte lysate (LAL) assay for endotoxin in hepatitis B vaccines and the effect of aluminum hydroxide. Biologicals 33 (2005) 145-151
41. Gheesling L.L., Carlone G.M., Pais L.B., Holder P.F., Maslanka S.E., Plikaytis B.D., et al. Multicentre comparison of Neisseria meningitides serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. J Clin Microbiol 32 (1994) 1475-1482
42. Goldblatt D. Simple solid phase assays of avidity. In: Turner M.W., and Jonh-stone A.P. (Eds). Immunochemistry. 2. A practical approach (1997), IRL Press at Oxford University Press, Oxford 31-51
43. Milagres L.G., Ramos S.R., Sacchi C.T., Melles C.E., Vieira V.S., Sato H., et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun 62 (1994) 4419-4424
44. Bhattacharjee A.K., Jennings H.J., Kenny C.P., Martin A., and Smith I.C.P. Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroups B and C with carbon 13 nuclear magnetic resonance. J Biol Chem 250 (1983) 1926-1932
45. 1H NMR assignment and detailed O-acetylation patterns of capsular polysaccharides from Neisseria meningitidis used in vaccine production. Carbohydr Res 296 (1996) 83-96
46. Jones C., and Lemercinier X. Use and validation of NMR assays for the identity and O-acetyl content of capsular polysaccharides from Neisseria meningitidis used in vaccine manufacture. J Pharm Biomed Anal 30 (2002) 1233-1247
47. Girard M.P., Preziosi M.-P., Aguado M.-T., and Kieny M.P. A review of vaccine research and development: meningococcal disease. Vaccine 24 (2006) 4692-4700
48. Cuervo M.L.C., Pérez L.R., Oviedo M., Costa L., and Perdomo V. Relationships among physico-chemical and biological tests for a synthetic Hib-TT conjugate vaccine. Vaccine 25 (2007) 194-200
49. Beuvery E.C., Delft R.W., Miedema F., Kanhai V., and Nagel J. Immunological evaluation of meningococcal group C polysaccharide-tetanus toxoid conjugate in mice. Infect Immun 41 (1983) 609-617
50. Cuello M., Cabrera O., Martinez I., del Campo J.M., Parajón E., Sotolongo F., et al. Mucosal immune responses to meningococcal C polysaccharide-protein conjugate in mice. Vaccine (2006) 24S2:S2/72-S2/73
51. Anderson P.W., Pichichero M.E., Insel R.A., Betts R., Eby R., and Smith H. Vaccines consisting of periodate-cleaved oligosaccharides from the capsule of Haemophilus influenzae type b coupled to a protein carrier: structural and temporal requirements for priming in the human infant. J Immunol 137 (1986) 1181-1186
52. Wang J.Y., Chang A.H.C., Guttormsen H.-K., Rosas A.L., and Kasper D.L. Construction of designer glycoconjugate vaccines with size-specific oligosaccharide antigens and site-controlled coupling. Vaccine 21 (2003) 1112-1117
53. Carmenate T., Guirola M., Alvarez A., Canaán L., González S., Caballero E., et al. Memory immune response generated in Cercopithecusaethiops against meningococcal polysaccharide serogroup C conjugate vaccine. FEMS Immunol Med Microbiol 43 (2005) 133-140
54. Borrow R., Andrews N., Goldblatt D., et al. serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: re-evaluation of correlates of protection. Infect Immun 69 (2001) 1568-1573
55. Borrow R., Palmer P., and Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 23 (2005) 2222-2227
56. Cuello M., Cabrera O., Martinez I., del Campo J.M., Camaraza M.A., Sotolongo F., et al. New meningococcal C polysaccharide-tetanus toxoid conjugate. Physico-chemical and immunological characterization. Vaccine 25 (2007) 1798-1805
57. Ritcher M.Y., Jakobsen H., Birgisdottir A., Haeuw J.-F., Power U.F., Giudice G., et al. Immunization of female mice with glycoconjugates protects their offspring against encapsulated bacteria. Infect Immun 72 (2004) 187-195
58. Carmenate T., Canaán L., Álvarez A., Delgado M., González S., Menéndez T., et al. Effect of conjugation methodology on the immunogenicity and protective efficacy of meningococcal group C polysaccharide-P64K protein conjugates. FEMS Immunol Med Microbiol 40 (2004) 193-199
59. Harris S.L., Finn A., and Granoff D.M. Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitides-diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine. Infect Immun 71 (2003) 3402-3408
60. McCloskey N., Turner M.W., and Goldblatt T.D. Correlation between the avidity of mouse-human chimeric IgG subclass monoclonal antibodies measured by solid-phase elution ELISA and biospecific interaction analysis (BIA). J Immunol Methods 205 (1997) 67-72
61. Aase A., Naess L.M., Sandin R.H., Herstad T.K., Oftung F., Holst J., et al. Comparison of functional immune responses in humans after intranasal and intramuscular immunizations with outer membrane vesicle vaccines against group B meningococcal disease. Vaccine 21 (2003) 2042-2051
62. Wang Y., Huang G., Wang J., Molina H., Chaplin D.D., and Fu Y.X. Antigen persistence is required for somatic mutation and affinity maturation of immunoglobulin. Eur J Immunol 30 (2000) 2226-2234
63. Burrage M., Robinson A., Borrow R., Andrews N., Southern J., Findlow J., et al. Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun 70 (2002) 4946-4954
64. Vermont C.L., van Dijken H.H., de Groot R., van Alphen L., and van den Dobbelsteen G.P.J.M. PorA-specific differences in antibody avidity after vaccination with a hexavalent Men B outer membrane vesicle vaccine in toddlers and school children. Vaccine 22 (2004) 3008-3013